Imatinib Stada

Imatinib, the active ingredient in Imatinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients. Imatinib Stada works by blocking key enzymes that drive the growth of malignant cells, providing a targeted therapeutic option for these cancers.

GNH USA supplies Imatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on malignant cells that depend on BCR‑ABL, c‑KIT or PDGFR signaling pathways. It is indicated for the following conditions: - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by targeting BCR‑ABL driven blasts. - Gastrointestinal stromal tumor (GIST): inhibits c‑KIT/PDGFR activity to control tumor growth.

Adverse reactions may occur with Imatinib therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often of the hands or feet. - Fatigue: reduced energy levels and general tiredness.

Serious or Rare Side Effects: - Hepatic toxicity: elevated liver enzymes or hepatitis. - Severe neutropenia: marked reduction in white blood cells. - Cardiac failure: signs of reduced cardiac function. - Pulmonary hypertension: increased pressure in lung arteries. - Tumor lysis syndrome: rapid tumor cell breakdown. - Anaphylaxis: severe allergic reaction requiring immediate care.

Patients receiving Imatinib should be monitored closely for safety concerns. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: check hepatic enzymes periodically. - Evaluate cardiac status: watch for signs of heart failure or hypertension. - Avoid use in known hypersensitivity: discontinue if severe allergic reaction occurs. - Store at below 25°C: keep in the original pack, protect from moisture.

Imatinib may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase imatinib exposure. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Antacids containing aluminum or magnesium: can lower absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Proton pump inhibitors: may modestly affect plasma concentration, observe clinical response.